Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

Quick Access

Favorites
Most Used

All Specialties

OpiCalc Logo
Clinical CalculatorsDrugsGuidelines
SpecsDrugsGuides
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Registry Hub
Centrally Acting Alpha-2 Agonist Antihypertensive/Discontinued

GUANABENZ ACETATE

GUANABENZ ACETATE

Clinical safety rating

caution

Comprehensive clinical and safety monograph for GUANABENZ ACETATE (GUANABENZ ACETATE).


Mechanism of Action

Central alpha-2 adrenergic agonist; reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and heart rate.

What the body does with it

MetabolismPrimarily hepatic via glucuronidation and oxidation; CYP450 involvement minimal.
ExcretionRenal: ~75% as unchanged drug and metabolites; biliary/fecal: ~25%.
Half-lifeTerminal elimination half-life is 7-12 hours; requires twice-daily dosing for stable antihypertensive effect.
Protein bindingApproximately 90% bound to albumin and α1-acid glycoprotein.
Volume of Distribution2-3 L/kg, indicating extensive tissue distribution.
BioavailabilityOral: ~85% (well absorbed, minimal first-pass metabolism).
Onset of ActionOral: 30-60 minutes.
Duration of Action6-12 hours; clinical effect may persist for up to 24 hours with chronic dosing due to long half-life.
Molecular Weight291.13

Classification & Brands

Dosing & administration

4 mg orally twice daily, titrated up to 8-16 mg twice daily; maximum 32 mg twice daily.

Dosage formTABLET
Renal impairmentGFR 30-59 mL/min: reduce dose by 50%; GFR <30 mL/min: avoid use or use with extreme caution.
Liver impairmentChild-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use.
Pediatric useNot recommended; safety and efficacy not established in children.
Geriatric useInitiate at lower dose (2 mg twice daily) and titrate slowly due to increased risk of orthostatic hypotension and sedation.

Use during pregnancy

1st trimesterAvoid use in first trimester. Guanabenz crosses the placenta and animal studies have shown teratogenic effects. Human data are limited but risk cannot be excluded.
2nd trimesterUse only if potential benefit justifies risk. May cause fetal bradycardia and hypotension. Avoid near term.
3rd trimesterAvoid use in third trimester due to risk of neonatal hypotension, bradycardia, and withdrawal symptoms.

Clinical note

Comprehensive clinical and safety monograph for GUANABENZ ACETATE (GUANABENZ ACETATE).

Placental transferGuanabenz crosses the placenta; fetal plasma levels approximately 50-70% of maternal levels based on animal data.
BreastfeedingGuanabenz is excreted into breast milk in small amounts. Caution should be exercised as effects on the nursing infant are unknown. Monitor infant for potential hypotension, sedation, and feeding difficulties.
Lactation RatingL3 (Moderately Safe)
Teratogenic RiskFirst trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Risk of fetal bradycardia, hypotension, and decreased placental perfusion due to alpha-2 agonist activity. Avoid use unless benefit outweighs risk.
Fetal MonitoringMonitor maternal blood pressure and heart rate. Fetal heart rate monitoring after maternal dosing. Assess for signs of neonatal withdrawal (e.g., irritability, poor feeding) postpartum.
Fertility EffectsNo evidence of adverse effects on fertility in animal studies or human data. Reversible hyperprolactinemia reported, which may impair fertility.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to guanabenz or any component of the formulationConcurrent use with monoamine oxidase inhibitors (MAOIs)

Clinical Precautions

PrecautionsRebound hypertension upon abrupt discontinuation; sedation; orthostatic hypotension; syncope; use caution in hepatic impairment.
Food/DietaryNo significant food interactions reported. Avoid excessive alcohol intake, as it may enhance the hypotensive and sedative effects.

Clinical Tips & Counseling

Clinical PearlsGuanabenz is a centrally acting alpha-2 agonist similar to clonidine. Abrupt discontinuation can cause rebound hypertension. It may cause dry mouth, sedation, and dizziness. Use with caution in patients with severe coronary insufficiency, recent myocardial infarction, or cerebrovascular disease. Monitor blood pressure regularly. Tolerance may develop with long-term use.
Patient AdviceTake guanabenz exactly as prescribed. Do not stop suddenly without consulting your doctor, as this can cause a dangerous rise in blood pressure. · This medication may cause drowsiness or dizziness. Avoid driving or operating machinery until you know how it affects you. · Avoid alcohol and other central nervous system depressants (e.g., sedatives, tranquilizers) as they may increase sedation. · Dry mouth is common; suck on sugarless candy or ice chips to relieve discomfort. · Notify your doctor if you experience slow heartbeat, fainting, or swelling in your feet or legs. · Weigh yourself regularly and report rapid weight gain to your doctor. · Do not use over-the-counter cough, cold, or allergy products unless approved by your doctor, as they may contain ingredients that affect blood pressure.

GUANABENZ ACETATE Interactions

Loading safety data…

This overview is compiled from peer-reviewed clinical sources and FDA labeling. It's here to support — not replace — clinical judgment. Always verify dosing against your institution's current protocols before prescribing.

On this page

Mechanism of ActionDosing & administrationUse during pregnancyWarnings & precautionsDrug interactions

External sources

DailyMed (NIH) PubMed OpenFDA